IE
SGMT icon

Israel Englander’s Sagimet Biosciences SGMT Stock Holding History

Israel Englander’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-87,800
Closed -$669K – 6420
2025
Q2 		$669K Buy
+87,800
New +$371K ﹤0.01% 4700

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Israel Englander's SGMT Position: Q2 2026 in Review

Israel Englander increased its Sagimet Biosciences (SGMT) stake by 8.7% in Q2 2026, buying an estimated $508K and bringing the position to 937,025 shares worth $7.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

Israel Englander first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. 121 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Israel Englander held 937,025 shares of Sagimet Biosciences worth $7.24M as of Q2 2026.
  • Israel Englander bought 74,722 Sagimet Biosciences shares in Q2 2026, an estimated $508K.
  • Sagimet Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2645 holding.
  • Israel Englander first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 121 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.